Scientific editorial illustration of edible mushrooms, a cell-membrane transporter and mitochondrial redox biology
Geroprotect Blog

Geroprotect research note · Evidence review

L-Ergothioneine: The Diet-Derived ‘Longevity Vitamin’?

Transport, human evidence, MPST and NAD+—with the longevity hypothesis kept in its proper evidence tier

Abstract

L-ergothioneine is a diet-derived sulfur-containing amino-acid derivative that humans actively absorb through SLC22A4, commonly called OCTN1 or the ergothioneine transporter. That transport biology makes ergothioneine unusually interesting. It does not make the molecule an established vitamin, a treatment, or a proven longevity intervention.

The strongest human findings are pharmacokinetic and observational. Oral ergothioneine raises plasma and whole-blood concentrations and is retained with low urinary loss. Higher plasma concentrations have been associated with lower mortality and slower cognitive decline, but those studies cannot prove causation. A 19-person cognitive pilot generated encouraging signals but was drastically underpowered; only 14 participants completed it. A larger 147-person trial raised plasma ergothioneine yet missed its primary composite-memory endpoint. Recent MPST and CSE–persulfidation studies provide sophisticated mechanisms in cells and animals, not evidence that those mechanisms improve human aging. Geroprotect Essentials II already contains 24 mg per full six-tablet serving; this article reviews that existing ingredient and makes no new dose or synergy recommendation.

01 · Identity

A dietary thione with an unusually selective transport system

L-ergothioneine is 2-mercaptohistidine trimethylbetaine. At physiological pH it exists predominantly in a thione rather than a free-thiol form, which helps explain its chemical stability. No human biosynthetic pathway is known; humans obtain it from food. Mushrooms are among the richest sources, while smaller and highly variable amounts occur in other foods; their share of an individual’s total intake depends on the diet and should not be reduced to a universal percentage.

The key discovery came in 2005. Gründemann and colleagues showed that SLC22A4, then called an organic-cation transporter, carries ergothioneine with high efficiency in a sodium-dependent system.1 In mice lacking Slc22a4, metabolomic analysis found near-complete ergothioneine deficiency across blood and sampled organs, while intestinal absorption and renal reabsorption were sharply reduced.2

A selective transporter is evidence that biology handles the molecule deliberately. It is not, by itself, evidence of essentiality or benefit from additional intake when status is already adequate. Transporters can also have multiple substrates, tissue expression varies, and concentrating a molecule does not tell us which clinical outcome—if any—supplementation will change.

02 · The hypothesis

What “longevity vitamin” means—and what it does not

Bruce Ames introduced “longevity vitamins” as a hypothesis: compounds that may not be required to prevent an immediate deficiency disease but might support proteins or processes important for long-term health. In his 2018 perspective, ergothioneine appeared among ten putative longevity vitamins.3

The adjective is doing important work. “Putative” means proposed. Ergothioneine has not been assigned vitamin status by nutrition authorities, no specific human deficiency syndrome has been established, and no trial shows that correcting a low ergothioneine value extends life. The hypothesis is credible enough to test because humans absorb and retain the molecule, blood concentrations vary with age and health, and several animal models are positive. It should remain a hypothesis until causal human evidence arrives.

03 · Human exposure

Oral ergothioneine reaches blood and stays there

A placebo-controlled pharmacokinetic study randomized 45 healthy men aged 21 to 35 to placebo, 5 mg or 25 mg of ergothioneine daily for seven days. Plasma and whole-blood concentrations rose, urinary excretion was below 4% of the administered amount, and hercynine and S-methyl-ergothioneine tracked with exposure. Biomarkers of oxidative damage and inflammation mostly showed non-significant downward trends.4

This is strong evidence for absorption and retention. It is not evidence that a higher plasma concentration is inherently better, that every tissue reaches a therapeutic concentration, or that the molecule improved health. Pharmacokinetics answers “did the exposure change?” Clinical efficacy asks “did a meaningful outcome improve compared with a suitable control?”

04 · Observational evidence

Mortality and cognition: consistent signals with unresolved causality

The Malmö cohort

In 3,236 adults without baseline cardiovascular disease or diabetes from the Malmö Diet and Cancer study, plasma ergothioneine was the metabolite most strongly associated with a health-conscious food pattern. Over a median 21.4 years, each one-standard-deviation higher concentration was associated with lower coronary-disease risk (hazard ratio 0.85), cardiovascular mortality (0.79) and all-cause mortality (0.86) after multivariable adjustment.5

The duration and event count make this important epidemiology. It remains epidemiology. Ergothioneine may partly mark a broader dietary pattern, renal handling, metabolic health or other unmeasured differences. Adjustment reduces confounding; it cannot remove every confounder or prove that supplementation would reproduce the association.

The Singapore memory-clinic cohort

Among 470 older adults attending memory clinics, lower baseline plasma ergothioneine was associated with poorer baseline cognition and faster decline over follow-up of up to five years across memory, executive function, attention, visuomotor speed and language. Associations were concentrated in non-demented participants. Mediation analyses suggested that cerebrovascular disease and brain atrophy explained much of the relationship.6

That pattern can support ergothioneine as a prognostic biomarker and motivate a trial. It cannot show whether low ergothioneine contributes to pathology, pathology lowers ergothioneine, diet influences both, or several processes act together.

05 · Human intervention

One underpowered pilot and one informative primary null

The 19-person MCI pilot

A randomized, double-blind pilot assigned 19 adults aged 60 or older with mild cognitive impairment to 25 mg of ergothioneine or placebo three times weekly for one year. Only 14 completed the study; the original sample-size calculation called for 106 participants. The ergothioneine group showed signals in Rey Auditory Verbal Learning Test performance and plasma neurofilament light chain, while routine blood, liver and kidney safety markers did not materially change.7

Those findings are hypothesis-generating. With five withdrawals, very small arms, missed measurements during the COVID-19 period, numerous cognitive and biomarker outcomes, and a sample far below the planned size, the study cannot establish that ergothioneine delays cognitive decline or neuronal damage. Its one-year exposure is useful for this small selected group, but it does not settle population-wide chronic safety.

The 147-person dose-ranging trial

A 16-week randomized, double-blind trial enrolled 147 adults aged 55 to 79 with subjective memory complaints. Participants received placebo, 10 mg/day or 25 mg/day. Plasma ergothioneine rose dose- and time-dependently—about sixfold at week 16 with 10 mg and sixteenfold with 25 mg. The primary composite-memory endpoint, however, showed no significant treatment effect and no benefit versus placebo at week 16. A within-group improvement in the 25 mg arm at week 4 was not sustained.8

Several secondary or exploratory results were nominally favourable, including a reaction-time interaction, per-protocol subjective prospective-memory and sleep-initiation measures, and within-group biomarker changes. Other findings cut the other way: psychomotor speed favoured placebo over 10 mg in the per-protocol analysis, and visual memory declined within the 10 mg group. The study found no between-group telomere-length difference. These mixed secondary results do not overturn the primary null.

06 · Mechanism

MPST and persulfidation changed the mechanistic conversation

MPST in exercise-trained mouse muscle

A 2025 Cell Metabolism study used exercise-trained mice, metabolomics and proteome-wide thermal-stability methods to identify 3-mercaptopyruvate sulfurtransferase (MPST) as a direct ergothioneine target. Ergothioneine bound and activated MPST, increased mitochondrial respiration and improved exercise-training performance in mice.9 This is unusually specific target evidence. It is still a mouse exercise experiment, not proof of universal mitochondrial accumulation or improved human performance.

CSE, hydrogen sulfide, persulfidation and NAD+

A separate 2025 study proposed ergothioneine as an alternative substrate for cystathionine gamma-lyase (CSE), increasing hydrogen-sulfide signalling and persulfidation across hundreds of protein targets. Activation of cytosolic glycerol-3-phosphate dehydrogenase contributed to higher NAD+ in model systems. In nine-month-old male rats, 20 mg/kg in drinking water for three weeks increased the muscle NAD+/NADH ratio and improved endurance and muscle measures; dependence on CSE or cGPDH was tested in complementary systems.10

The precision of the pathway does not solve translation. A 20 mg/kg rat exposure is not the 24 mg human formula amount, muscle NAD+/NADH is not lifespan, and no human trial has shown that oral ergothioneine raises tissue NAD+ through this pathway. The cited paper did not test an ergothioneine-plus-NMN combination, and it did not test Geroprotect.

07 · Lifespan

One positive male-mouse study needs replication

A 2024 study supplied male C57BL/6J mice with ergothioneine in drinking water from seven weeks of age for life, at an estimated 4–5 mg/kg/day. The survival experiment included 36 treated and 35 control mice. Ergothioneine extended lifespan in that cohort and improved several late-life movement, frailty, plasma-biomarker and hippocampal measures.11

That is stronger than a cell result and deserves attention. It is also one inbred strain, one sex, one laboratory and one lifelong schedule beginning in youth. It has not been independently replicated, and no NIA Interventions Testing Program result for ergothioneine was identified as of 14 July 2026. No human lifespan or validated healthspan trial exists.

08 · Safety and regulation

Regulatory decisions are specific to ingredient, use and jurisdiction

The US FDA responded to GRAS Notice 734 in 2018 with “no questions” regarding the notifier’s conclusion for ergothioneine used in specified conventional foods at levels intended to provide 5 mg per serving.12 A no-questions letter is not FDA approval of a supplement, an efficacy endorsement, or a safety determination for every source, dose and finished formulation.

European Union novel-food conditions authorize L-ergothioneine in food supplements at up to 30 mg/day for the general adult population, excluding pregnant and lactating women, and 20 mg/day for children older than three.13 Those are EU conditions of use, not a universal dosing recommendation. Product source specifications and local regulations still matter.

Drug-interaction evidence is thin. In an open-label fixed-sequence study of ten healthy men, a high-shiitake diet modestly increased gabapentin renal clearance but did not change total gabapentin exposure by AUC. The meal contained many constituents, so the effect cannot be assigned to ergothioneine alone.14 This does not establish a clinically important gabapentin interaction, and the reviewed evidence does not support a pregabalin warning. People using prescription medicines should still discuss supplements with a pharmacist or clinician because absence of evidence is not a complete interaction assessment.

09 · Formula context

Ergothioneine is already in Essentials II

A full six-tablet daily serving of Geroprotect Essentials II contains 24 mg of L-ergothioneine. It is not a missing layer proposed for a future stack; it is one of the current 13 Essentials II actives. The amount is close to doses used in recent human trials and falls below the EU’s 30 mg/day adult novel-food condition, but neither comparison proves efficacy or long-term safety of the finished formula.

No controlled study has compared Essentials II with its components, tested Essentials I plus Essentials II against either formula alone, or demonstrated that L-ergothioneine is synergistic with NR, NMN, CoQ10, PQQ, urolithin A or any other ingredient. The finished combination should therefore be described as a formulation rationale, not a validated intervention.

StatementEvidence boundary
Humans absorb and retain ergothioneineSupported by a controlled seven-day pharmacokinetic study.
Higher ergothioneine predicts lower mortalitySupported as an adjusted observational association; causality is unproven.
Ergothioneine improves cognitionNot established. A tiny pilot was encouraging; the larger trial missed its primary endpoint.
Ergothioneine raises NAD+ in humansUnproven. CSE–cGPDH evidence is from cells, worms and rats.
Ergothioneine extends lifespanPositive in one male-mouse study; not established in humans.
The Geroprotect combination is synergisticUntested. No finished-formula or component-controlled trial exists.

Questions

Frequently asked questions

Is L-ergothioneine an official vitamin?

No. “Longevity vitamin” is Bruce Ames’s putative category, not an official nutrient classification. The transporter and retention data make the hypothesis interesting, but no human deficiency syndrome or longevity benefit has been established.

Did the 147-person trial improve memory?

Not on its primary endpoint. The 25 mg group improved from its own baseline at week 4, but the effect was not sustained to week 16 and did not differ from placebo. Some secondary measures were favourable, others were null or favoured placebo.

Does Essentials II contain L-ergothioneine?

Yes. A full six-tablet serving contains 24 mg. This article reviews an existing formula ingredient; it does not propose adding ergothioneine or increasing its dose.

Does L-ergothioneine work synergistically with NMN or NR?

That has not been demonstrated. Recent animal work links ergothioneine to NAD+ metabolism, but no component-controlled human trial shows synergy with NMN, NR or the Geroprotect formulas.

Does L-ergothioneine interact with gabapentin or pregabalin?

A ten-person high-shiitake study modestly changed gabapentin renal clearance but not total exposure, and it could not isolate ergothioneine from other food constituents. No evidence reviewed here supports a pregabalin claim. Ask a pharmacist or clinician for advice specific to your medicines.

Sources

References

  1. Gründemann D, et al. Discovery of the ergothioneine transporter. Proceedings of the National Academy of Sciences USA. 2005;102:5256–5261. PMID 15795384.
  2. Kato Y, et al. Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. Pharmaceutical Research. 2010. PMID 20224991.
  3. Ames BN. Prolonging healthy aging: longevity vitamins and proteins. Proceedings of the National Academy of Sciences USA. 2018;115:10836–10844. PMID 30322941. Perspective proposing, not establishing, the category.
  4. Cheah IK, et al. Administration of pure ergothioneine to healthy human subjects: uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation. Antioxidants & Redox Signaling. 2017;26:193–206. PMID 27488221.
  5. Smith E, et al. Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. Heart. 2020;106:691–697. PMID 31672783.
  6. Wu LY, et al. Low plasma ergothioneine predicts cognitive and functional decline in an elderly cohort attending memory clinics. Antioxidants. 2022;11:1717. PMID 36139790.
  7. Yau YF, et al. Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: a pilot study. Journal of Alzheimer’s Disease. 2024;102:841–854. PMID 39544014; trial NCT03641404.
  8. Zajac IT, et al. The effect of ergothioneine supplementation on cognitive function, memory, and sleep in older adults with subjective memory complaints: a randomized placebo-controlled trial. Nutraceuticals. 2025;5:15. Trial ACTRN12621001607864.
  9. Sprenger HG, et al. Ergothioneine controls mitochondrial function and exercise performance via direct activation of MPST. Cell Metabolism. 2025;37:857–869. PMID 39965563.
  10. Petrovic D, et al. Ergothioneine improves healthspan of aged animals by enhancing cGPDH activity through CSE-dependent persulfidation. Cell Metabolism. 2025;37:542–556.e14. PMID 39842434.
  11. Katsube M, et al. Ergothioneine promotes longevity and healthy aging in male mice. GeroScience. 2024;46:3889–3909. PMID 38446314.
  12. US Food and Drug Administration. GRAS Notice 734: Ergothioneine; FDA response “no questions.” Closed 7 May 2018. Intended conventional-food uses at 5 mg per serving.
  13. European Commission. Commission Implementing Regulation (EU) 2018/462: authorised conditions of use for L-ergothioneine. 2018.
  14. Toh DSL, et al. Effect of mushroom diet on pharmacokinetics of gabapentin in healthy Chinese subjects. British Journal of Clinical Pharmacology. 2014;78:129–134. PMID 24168107.

Quality you can check

Every badge links to the document behind it: manufacturer certificates, certificates of analysis for all 26 actives, and our own promises about the formula.

Huazhen Biotechnology (Shenzhen) holds ISO 22000:2018 certificate 015FSMS2400550 and HACCP certificate 015HACCP2400460, both valid until 2 December 2027. These are manufacturer system papers, not a product certificate. The earlier papers 150FSMS2200001 and 150HACCP2200001 ended in March 2025 and are not shown as valid. Halal certificates cover raw materials from our suppliers; Geroprotect Essentials is not registered as a halal product. Food supplement. Read the current product label before use.

Bought from Geroprotect? Leave an honest review:Review us on TrustpilotReview us on GoogleReview on Amazon.aeReviews are optional and never rewarded. More about reviews.
Scroll to Top